Gene-Edited immune cells take aim at stubborn lymphoma
NCT ID NCT05169489
Summary
This early-stage study tested a new type of CAR T-cell therapy called bbT369 in adults with aggressive B-cell lymphoma that had come back or not responded to at least two prior treatments. The therapy involves modifying a patient's own immune cells to better target and fight the cancer. The main goal was to check the safety of the treatment and see if it showed any signs of being effective against the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Sarah Cannon
Nashville, Tennessee, 37203, United States
-
Stanford Cancer Institute
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.